Planview Announces Strategic Acquisitions of Clarizen and Changepoint to Accelerate Strategy to Delivery for Enterprises
Planview, a global leader in Portfolio Management and Work Management, today announced the company has entered into definitive agreements to acquire Clarizen and Changepoint, leading enterprise Project Portfolio Management (PPM) providers.
Across industries, enterprises are transforming their businesses to be digital-first. This shift has only accelerated during the COVID-19 pandemic, and what’s emerged is a new and enduring way of working that’s flexible, highly distributed, and digital. As increasingly dispersed teams embrace new tools and processes to meet the evolving needs of their customers, visibility and connectivity across the enterprise have never been more critical. The market demands a comprehensive software platform that can connect strategy to delivery across siloed workstreams and disciplines – capabilities best provided through PPM and Agile.
The combination of Planview, Clarizen, and Changepoint creates a unique platform enabling organizations to better collaborate, deliver, and thrive in this new world of work. Backed by TPG Capital and TA Associates, the combination harnesses the capabilities of three leading providers to deliver customers an unmatched level of expertise, IP, and resources to ensure their most important outcomes are delivered with efficiency, urgency, and transparency.
“In today’s environment, enterprises are looking for partners with the vision, expertise, and scale to help them navigate and excel in our all-digital world,” said Greg Gilmore, CEO of Planview. “Planview, Clarizen, and Changepoint are all leaders, and together, our customers create an exceptional community of PMOs, PPM and Professional Services Automation (PSA) practitioners. Collectively, there is no better platform to drive innovation and fuel the transformation of strategy to delivery.”
Since inception, Planview has focused on partnering with enterprises to help them re-imagine the ways they plan and manage work. With Clarizen and Changepoint’s leadership and category expertise, Planview will provide customers of all sizes with a robust community and end-to-end offering that enables them to meet their unique business goals and drive better business outcomes. In addition to leading Enterprise Agile Planning and Kanban from Planview, Clarizen and Changepoint customers will benefit from the expanded resources that Planview delivers.
“We’re thrilled to be joining forces with two organizations that share our core belief of putting customers at the heart of everything we do,” said Matt Zilli, CEO of Clarizen. “By bringing together these companies, customers will have access to a portfolio of industry leading solutions from three world-class companies, as well as new innovation as we focus on providing even more value to our customers.”
“In order to achieve meaningful business outcomes, organizations need to be adaptable and nimble while ensuring alignment from strategic planning to delivery,” said Matt Scheuing, CEO of Changepoint. “We look forward to working with the Planview and Clarizen teams and believe the combination of exceptional Portfolio and Work Management solutions, practitioners and experts will enable our customers to continue to succeed in an ever-changing business environment.”
Upon completion of the transactions, the Clarizen and Changepoint teams will join Planview as distinct business units, led by Matt Zilli and Matt Scheuing. Zilli and Scheuing will report into Planview CEO, Greg Gilmore. The transaction is expected to close in the first quarter of 2021. Terms of the transaction were not disclosed. To learn more, visit Planview.com.
About Planview
Planview has one focus: enabling the transformation journey as organizations rewire strategy to delivery in today’s fast-paced, highly disruptive markets. Our solutions enable organizations to navigate this journey and accelerate on-strategy delivery at enterprise scale. Planview’s full spectrum of Portfolio Management and Work Management solutions create organizational focus on the strategic outcomes that matter and empower teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enable customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, Planview has more than 700 employees supporting 3,500 customers and 1 million users worldwide. For more information, visit: www.planview.com.
About Clarizen
Clarizen connects work across the enterprise, turning ideas into strategies, plans, and action. With Clarizen, organizations can work the way they want to work and have real time visibility into all their workstreams. This keeps teams focused on the things that matter, delivers results faster, and helps them exceed their company goals and customers’ expectations. Thousands of global customers, such as Jones Lang LaSalle (JLL), Siemens, De Beers, Ricoh, Box and Shaw Industries, across a wide variety of industries in 124 countries rely on Clarizen to help them achieve their business goals. To learn more, visit www.clarizen.com.
About Changepoint
Changepoint transforms project, engagement and application portfolios with an adaptable, intuitive and intelligent platform that is configurable for an agile business. Changepoint’s built-for-purpose portfolio management solutions are designed for strategic transformation leaders, project management offices, services organizations, and IT leaders. Hundreds of global customers partner with us to make informed and innovative business decisions, enable transformation, maximize profit, drive visibility, and align outcomes to strategy. Achieve better business outcomes at www.changepoint.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210112005685/en/
Contact information
Planview
Leslie Marcotte
719-439-4921
lmarcotte@planview.com
Clarizen
Andrew Ryan, Actual Agency
954-495-6786
andrew.ryan@actual.agency
Changepoint
Andy Tolton
425-681-2770
andy.tolton@changepoint.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom